期刊
CLINICAL INFECTIOUS DISEASES
卷 53, 期 -, 页码 S33-S55出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir475
关键词
-
资金
- Consensus Medical Communication
- Astellas
- Sanofi Pasteur
- Astrazeneca
- Therafan
- Forest Laboratories and Novartis
- TRIUS
- Covidien
- BARD
- National Heart, Lung, and Blood Institute [K23HL096054]
- University of Colorado School of Medicine
- Consensus Medical Communications
- Ortho-McNeil Janssen Scientific Affairs, LLC.
- Merck
- Cubist
- Pfizer
- Johnson Johnson
- National Heart, Lung, and Blood Institute
- GlaxoSmithKline
The emerging problem of antibiotic resistance, especially among Gram-negative bacteria (GNB), has become a serious threat to global public health. Very few new antibacterial classes with activity against antibiotic-resistant GNB have been brought to market. Renewed and growing attention to the development of novel compounds targeting antibiotic-resistant GNB, as well as a better understanding of strategies aimed at preventing the spread of resistant bacterial strains and preserving the efficacy of existing antibiotic agents, has occurred. The Gram-Negative Resistance Summit convened national opinion leaders for the purpose of analyzing current literature, epidemiologic trends, clinical trial data, therapeutic options, and treatment guidelines related to the management of antibiotic-resistant GNB infections. After an in-depth analysis, the Summit investigators were surveyed with regard to 4 clinical practice statements. The results then were compared with the same survey completed by 138 infectious disease and critical care physicians and are the basis of this article.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据